The following amendment has been
made to the publication of Block Listing Six Monthly Return
released on 26/04/24 at 7:00AM under RNS No
1211M.
The figure in the first table under
"Equals: Balance under scheme(s)
not yet issued/allotted at end of period" is 803,006, not 911,730
as announced.
The figure in the second table under
"Equals: Balance under scheme(s)
not yet issued/allotted at end of period" is 9,719,257, not
11,777,257 as announced.
All other details remain
unchanged.
The full amended text is shown
below.
26 April
2024
Avacta Group
plc
("Avacta"
or "the Group" or "the Company")
Block Listing Six Monthly
Return
Avacta Group plc (AIM: AVCT), a
life sciences developing innovative, targeted oncology drugs and
powerful diagnostics, today makes the
following notification pursuant to Schedule Six of the AIM Rules
for Companies regarding its existing block admission
arrangements:
|
Name of applicant:
|
Avacta Group plc
|
|
Name of scheme:
|
EMI scheme
|
|
Period of return:
|
From:
|
28 October 2023
|
|
27 April 2024
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
797,922
|
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
113,808
|
|
Less: Number
of securities issued/allotted
under scheme(s) during period (see LR3.5.7G):
|
108,724
|
|
Equals: Balance under scheme(s)
not yet issued/allotted at end of period:
|
803,006
|
|
|
|
|
|
|
|
Name of applicant:
|
Avacta Group plc
|
|
Name of scheme:
|
LTIP scheme
|
|
Period of return:
|
From:
|
28 October 2023
|
|
27 April 2024
|
|
Balance of unallotted securities
under scheme(s):
|
5,277,257
|
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
6,500,000
|
|
Less: Number
of securities issued/allotted
under scheme(s) during period (see LR3.5.7G):
|
2,058,000
|
|
Equals: Balance under scheme(s)
not yet issued/allotted at end of period:
|
9,719,257
|
|
|
|
|
|
|
|
Name of contact:
|
Tony Gardiner, Company
Secretary
|
|
Telephone number of
contact:
|
+ 44 (0) 1904 217070
|
Ends-
For
further information from Avacta Group plc, please
contact:
|
Avacta Group plc
Alastair Smith, Chief Executive
Officer
Tony Gardiner, Chief Financial
Officer
Michael Vinegrad, Group
Communications Director
|
Tel: +44
(0) 1904 21 7070
www.avacta.com
|
|
Stifel Nicolaus Europe
Limited (Nomad and Joint Corporate Broker)
Nicholas Moore / Nick Adams / Samira
Essebiyea / Nick Harland / Ben Good
|
Tel: +44
(0) 207 710 7600
www.stifel.com
|
|
Peel Hunt (Joint Corporate
Broker)
James Steel / Chris Golden / Patrick
Birkholm
|
Tel: +44
(0) 207 418 8900
www.peelhunt.com
|
|
ICR Consilium (Media and
IR)
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
|
avacta@consilium-comms.com
|
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based life
sciences company focused on improving healthcare outcomes through
targeted cancer treatments and diagnostics.
Avacta has two divisions focused on
therapeutics and diagnostics.
Avacta Therapeutics: a clinical
stage oncology biotech division harnessing proprietary therapeutic
platforms to develop novel, highly targeted cancer
drugs.
Avacta Diagnostics: focused on
supporting healthcare professionals and broadening access to
diagnostics.
Avacta has two proprietary
platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly
specific substrate for fibroblast activation protein (FAP) which is
upregulated in most solid tumours compared with healthy tissues.
The pre|CISION™ platform harnesses this tumour specific protease to
activate pre|CISION™ peptide drug conjugates and pre|CISION™
antibody/Affimer® drug conjugates in the tumour microenvironment,
reducing systemic exposure and toxicity, allowing dosing to be
optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme
AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase
1 studies. It has shown a dramatic improvement in safety and
tolerability in clinical trials to date compared with standard
doxorubicin and preliminary signs of clinical activity in multiple
patients.
To register for news alerts by email
go to https://avacta.com/investors/investor-news-email-alerts/